Hizentra is the first subcutaneous immunoglobulin proven to prevent CIDP relapse.
People taking Hizentra:
Appolos
With IVIg dosing every 3 weeks, you may experience highs and lows between infusions—which can feel like being on a rollercoaster.
Hizentra weekly dosing provides smaller doses more frequently than IVIg. More consistent Ig levels may reduce potential for CIDP symptom return between infusions.
of Hizentra infusions were completed without any reported side effects
In a clinical trial, patients experienced fewer systemic side effects per infusion (like headache and nausea) with Hizentra than with IVIg
In clinical trials for Hizentra, the most common side effects were redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting.
CIDP Doctor Discussion Guide
Download the guide and discuss
Hizentra with your doctor today
†Patient advocates are not healthcare professionals or medical experts. For medical questions, please contact your physician. Patient advocates are compensated by CSL Behring LLC. for their time and/or expenses.
Personalized Dosing
See how infusing with Hizentra can be customized to fit your individual needs
Understanding CIDP
Learn some basic info about CIDP, including tips for patients and caregivers
